IO Biotech(IOBT) - 2024 Q3 - Quarterly Results

Exhibit 99.1 IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights • Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating of -the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced melanoma on track with primary endpoint of progression free survival (PFS) projected to be reached in first half of 2025 • Primary endpoint met in Phase 2 basket trial (IOB-022/KN-D38) cohort evaluating IO10 ...